Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
An HPLC method has been developed and validated for the determination of spironolactone, 7 alpha-thiomethylspirolactone and canrenone in paediatric plasma samples. The method utilises 200 microl of plasma and sample preparation involves protein precipitation followed by Solid Phase Extraction (SPE). Determination of standard curves of peak height ratio (PHR) against concentration was performed by weighted least squares linear regression using a weighting factor of 1/concentration2. The developed method was found to be linear over concentration ranges of 30-1000 ng/ml for spironolactone and 25-1000 ng/ml for 7 alpha-thiomethylspirolactone and canrenone. The lower limit of quantification for spironolactone, 7 alpha-thiomethylspirolactone and canrenone were calculated as 28, 20 and 25 ng/ml, respectively. The method was shown to be applicable to the determination of spironolactone, 7 alpha-thiomethylspirolactone and canrenone in paediatric plasma samples and also plasma from healthy human volunteers.
Sandall
J M
JM
Clinical and Practice Research Group, School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97, Lisburn Road, Belfast BT9 7BL, UK.
Millership
J S
JS
Collier
P S
PS
McElnay
J C
JC
D002192:Canrenone / Q000097:blood* / Q000737:chemistry; D016022:Case-Control Studies; D002648:Child; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D006801:Humans; D012015:Reference Standards; D015203:Reproducibility of Results; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000097:blood* / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism*; D013997:Time Factors
D013148:Spironolactone; C046564:7-thiomethylspirolactone; D002192:Canrenone